GlobeNewswire

GEOFFREY J.W. KENT AND MANFREDI LEFEBVRE D’OVIDIO REACH AN AGREEMENT TO PURCHASE 100 PERCENT OF SHARES IN ABERCROMBIE & KENT

Share

Monaco, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Geoffrey J.W. Kent, Founder, Chairman and CEO of luxury travel company Abercrombie & Kent has formed a strategic partnership with Manfredi Lefebvre d’Ovidio, Chairman of Heritage group, to jointly acquire 100% of the Abercrombie & Kent Group of Companies S.A. (Abercrombie & Kent). This union brings together two visionaries in luxury travel to further develop Abercrombie & Kent as the premier brand in luxury and experiential travel.

Geoffrey Kent is a true pioneer and visionary in the travel industry. He created the first luxury tented photographic safaris in 1962 in Kenya and has built A&K into the world’s leading luxury and adventure travel company.

Manfredi Lefebvre built Silversea Cruises, created by his father in 1994 with the purchase of two ships, Silver Cloud and Silver Wind, into the leading luxury and expedition cruise line. Recently Royal Caribbean Group (RCL) acquired a 66% stake in Silversea Cruises. A&K is a separate and unique investment by Heritage group, led by Manfredi Lefebvre, and does not involve Silversea.

Since their humble beginnings, both companies have grown to become the dominant players in their respective fields, offering a discerning clientele the ultimate in luxury travel.

Geoffrey Kent and Manfredi Lefebvre have known each other for more than twenty years and also been business partners, having acquired the MV Explorer in 1992.

“Abercrombie & Kent is the finest luxury travel company in the world, and I am honored to be able to partner with Geoffrey Kent to help this remarkable company continue its record growth,” said Manfredi Lefebvre, Chairman of Heritage group. Kent added: “I am very excited to be working with Manfredi. I cannot think of a better or more experienced partner for the next phase of A&K’s growth.”

Heritage group will own 85% of Abercrombie & Kent and Geoffrey Kent 15%. Geoffrey Kent will continue to be Chairman and CEO of the operating company, while Manfredi Lefebvre will become Chairman of Abercrombie & Kent Holding.

The closing is expected to be completed later in the year, subject to customary closing conditions and regulatory approvals.

Barclays Bank Plc served as financial advisor to Heritage group.

# # #

Download high-resolution photos:

http://portfolio-galleries.abercrombiekent.com/media_relations

 

 

About Manfredi Lefebvre d’Ovidio de Cluniere di Balsorano

Chairman, Heritage group

Manfredi Lefebvre is Chairman of Heritage group as well as Executive Chairman of Silversea Cruises. The Lefebvre family conceived Silversea in the early ‘90s as a pioneering cruise line offering a personal style of ultra-luxury travel, unrivalled in the world. Silversea is now partially owned by Royal Caribbean Limited (RCCL). Mr. Lefebvre is also President of the Monegasque Chamber of Shipping, a Member of the Executive Committee of the World Travel & Tourism Council and a Member of the Board of Skuld. He was honoured with the Chevalier de l’Ordre de Saint Charles and Grimaldi by SAS Prince Albert of Monaco. www.heritagemonaco.com

About Geoffrey JW Kent

Founder, Chairman and CEO, Abercrombie & Kent

Geoffrey Kent’s life began much as he lives it today – amid excitement and adventure in an exotic location. He was born while his parents, Colonel John and Valerie Kent, were on safari in Northern Rhodesia (now Zambia). He grew up on the family farm in the Aberdare Highlands of Kenya and attended the then-new Duke of York School in Nairobi, which produced many of Kenya’s business and science leaders, including Richard Leakey. With the innate skill of an entrepreneur and the relentless curiosity of a born explorer, he built a company that enables travellers to discover the world around them – and to do it in a uniquely stylish manner. Geoffrey Kent was inducted into the UK’s Travel Hall of Fame and received a Lifetime Achievement Award from the US travel industry for creating “experiential travel” by bringing the same sense of adventure found on safari to destinations around the world. He recently published a book, Safari: A Memoir of a Worldwide Travel Pioneer.

About Abercrombie & Kent

Abercrombie & Kent pioneered luxury adventure travel with our first African safaris in 1962, and today A&K’s award-winning travel services extend around the globe to more than one hundred countries on all seven continents. A&K has more people in more places than any other travel company with more than 55 on-site offices in over 30 countries. www.abercrombiekent.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CESTPress release

Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPress release

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have